ifosfamide has been researched along with Cancer, Second Primary in 48 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS)." | 9.51 | Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. ( Chen, H; Chen, Y; Huang, M; Jiang, S; Liu, X; Luo, Z; Miao, J; Wang, C; Wang, H; Wang, J; Wu, X; Xia, J; Xu, Y; Yan, W; Yao, W; Yu, L; Zhang, X, 2022) |
| "This is the first instance of tumor lysis syndrome described in a patient with osteosarcoma undergoing ifosfamide monotherapy." | 9.22 | Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature. ( Chen, XT; Christ, AB; Hu, JS; Luminais, SN; Ma, B; Roman, D, 2022) |
| "Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor." | 7.73 | High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005) |
| "This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS)." | 5.51 | Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. ( Chen, H; Chen, Y; Huang, M; Jiang, S; Liu, X; Luo, Z; Miao, J; Wang, C; Wang, H; Wang, J; Wu, X; Xia, J; Xu, Y; Yan, W; Yao, W; Yu, L; Zhang, X, 2022) |
| "This is the first instance of tumor lysis syndrome described in a patient with osteosarcoma undergoing ifosfamide monotherapy." | 5.22 | Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature. ( Chen, XT; Christ, AB; Hu, JS; Luminais, SN; Ma, B; Roman, D, 2022) |
| "Patients with nonmetastatic osteosarcoma of the extremity were preoperatively treated with high-dose methotrexate, cisplatin, and doxorubicin (ADM)." | 5.09 | Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. ( Bacci, G; Bertoni, F; Campanacci, M; Casadei, R; Fabbri, N; Ferrari, S; Forni, C; Longhi, A; Picci, P; Ruggieri, P; Versari, M, 2000) |
| "Interval compression (IC), a regimen of alternating vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide every 2 weeks, improves survival for localized Ewing sarcoma (ES), with uncertain effect on metastatic disease." | 4.31 | Outcomes of Pediatric Patients With Metastatic Ewing Sarcoma Treated With Interval Compression. ( Ghandour, K; Halalsheh, H; Ibrahimi, AKH; Ismael, T; Sarhan, N; Shehadeh, A; Sultan, I; Zandaki, D, 2023) |
| "Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor." | 3.73 | High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005) |
| "Median age at diagnosis of Ewing sarcoma was 12 years, and median length of follow-up, 8 years." | 2.73 | Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. ( Askin, FB; Bhatia, S; Burden, L; Chen, Z; Dickman, PS; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Perlman, EJ; Rausen, AR; Robison, LL; Vietti, TJ, 2007) |
| "Six hundred ninety Ewing tumor patients were treated between 1992 and 1999 with local therapy and vincristine." | 2.70 | Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. ( Ahrens, S; Aulitzky, WE; Dunst, J; Fölsch, UR; Göbel, U; Harms, D; Hense, HW; Henze, G; Jürgens, H; Kremens, B; Lehnert, M; Niemeyer, C; Paulussen, M; Reiter, A; Taeger, D; Voûte, PA; Wagner, A; Zoubek, A, 2001) |
| "Poor-risk solid tumors were treated with four courses of cyclophosphamide (4,200 mg/m2)/ doxorubicin (75 mg/m2), and three courses of ifosfamide (9,000 mg/m2)/etoposide (500 mg/m2)." | 2.69 | High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. ( Bajorin, D; Cheung, NK; Heller, G; Kramer, K; Kushner, BH; Meyers, PA; Polyak, T; Wollner, N, 1998) |
| "There were four patients with pineoblastoma, two of whom had a positive familial history." | 2.44 | Trilateral retinoblastoma. ( Antoneli, CB; Arias, VE; Chojniak, MM; Novaes, PE; Ribeiro, Kde C; Sakamoto, LH, 2007) |
| "Thymomas and thymic carcinomas are unique tumors of the anterior mediastinum." | 2.41 | Thymic malignancies. ( Loehrer, PJ; Wick, MR, 2001) |
| "Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma." | 2.38 | Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993) |
| "(4) Characteristics of second neoplasms: Among the seven children with second neoplasms, five children had leukemia, 3 patients with rhabdomyosarcoma were combined with radiotherapy." | 1.72 | A report on second neo-plasms in seven children with solid tumors. ( Hu, H; Huang, D; Li, F; Li, J; Li, R; Liu, Z; Zhang, W, 2022) |
| " Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated." | 1.37 | Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. ( Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011) |
| "One patient developed a secondary acute myeloid leukemia (s-AML) involving a chromosomal translocation t(11;19)(q23;p13." | 1.33 | Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. ( Boehlke, I; Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Kuczyk, M; Metzner, B; Schleicher, J; Schleucher, N; Wierecky, J, 2005) |
| "The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas." | 1.30 | Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. ( Ahrens, S; Dunst, J; Harms, D; Jürgens, H; Paulussen, M; Rübe, C; Winkelmann, W; Zoubek, A, 1998) |
| "Six patients developed therapy-related acute myelogenous leukemia (t-AML)." | 1.30 | Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. ( Behnisch, W; Göbel, U; Hilgenfeld, E; Schneider, DT; Schwabe, D; Wessalowski, R; Zoubek, A, 1999) |
| "The authors report a case of pulmonary squamous cell carcinoma which occurred after chemotherapy of non-Hodgkin's lymphoma (NHL)." | 1.28 | [Elderly non-Hodgkin's lymphoma presenting with pulmonary squamous cell carcinoma as a complication of chemotherapy for malignant lymphoma]. ( Annoh, S; Arai, N; Kaneko, H; Shirai, T; Tsukahara, T; Umeda, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (29.17) | 18.2507 |
| 2000's | 22 (45.83) | 29.6817 |
| 2010's | 6 (12.50) | 24.3611 |
| 2020's | 6 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zandaki, D | 1 |
| Ismael, T | 1 |
| Halalsheh, H | 1 |
| Ibrahimi, AKH | 1 |
| Sarhan, N | 1 |
| Ghandour, K | 1 |
| Shehadeh, A | 1 |
| Sultan, I | 1 |
| Schoot, RA | 1 |
| Chisholm, JC | 1 |
| Casanova, M | 1 |
| Minard-Colin, V | 1 |
| Geoerger, B | 1 |
| Cameron, AL | 1 |
| Coppadoro, B | 1 |
| Zanetti, I | 1 |
| Orbach, D | 1 |
| Kelsey, A | 1 |
| Rogers, T | 1 |
| Guizani, C | 1 |
| Elze, M | 1 |
| Ben-Arush, M | 1 |
| McHugh, K | 1 |
| van Rijn, RR | 1 |
| Ferman, S | 1 |
| Gallego, S | 1 |
| Ferrari, A | 2 |
| Jenney, M | 1 |
| Bisogno, G | 1 |
| Merks, JHM | 1 |
| Luminais, SN | 1 |
| Chen, XT | 1 |
| Roman, D | 1 |
| Ma, B | 1 |
| Christ, AB | 1 |
| Hu, JS | 1 |
| Hu, H | 1 |
| Zhang, W | 1 |
| Li, J | 1 |
| Li, F | 1 |
| Li, R | 1 |
| Liu, Z | 1 |
| Huang, D | 1 |
| Liu, X | 1 |
| Jiang, S | 1 |
| Wang, H | 1 |
| Wu, X | 1 |
| Yan, W | 1 |
| Chen, Y | 1 |
| Xu, Y | 1 |
| Wang, C | 1 |
| Yao, W | 1 |
| Wang, J | 1 |
| Yu, L | 1 |
| Miao, J | 1 |
| Chen, H | 1 |
| Xia, J | 1 |
| Huang, M | 1 |
| Zhang, X | 1 |
| Luo, Z | 1 |
| Kajita, N | 1 |
| Saito, Y | 1 |
| Makimoto, A | 1 |
| Miyahara, S | 1 |
| Yuza, Y | 1 |
| Teepen, JC | 1 |
| van Leeuwen, FE | 1 |
| Tissing, WJ | 1 |
| van Dulmen-den Broeder, E | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| van der Pal, HJ | 1 |
| Loonen, JJ | 1 |
| Bresters, D | 1 |
| Versluys, B | 1 |
| Neggers, SJCMM | 1 |
| Jaspers, MWM | 1 |
| Hauptmann, M | 1 |
| van der Heiden-van der Loo, M | 1 |
| Visser, O | 1 |
| Kremer, LCM | 1 |
| Ronckers, CM | 1 |
| Kim, SH | 1 |
| Shin, KH | 1 |
| Seok, SO | 1 |
| Cho, YJ | 1 |
| Noh, JK | 1 |
| Suh, JS | 1 |
| Yang, WI | 1 |
| Yodoya, N | 1 |
| Iwamoto, S | 1 |
| Matsumine, A | 1 |
| Azuma, E | 1 |
| Toyoda, H | 1 |
| Miura, Y | 1 |
| Nakatani, K | 1 |
| Imai, H | 1 |
| Hirayama, M | 1 |
| Komada, Y | 1 |
| Mullah-Ali, A | 1 |
| Ramsay, JA | 1 |
| Bourgeois, JM | 1 |
| Hodson, I | 1 |
| Macdonald, P | 1 |
| Midia, M | 1 |
| Portwine, C | 1 |
| Gutweiler, JR | 1 |
| Yu, DC | 1 |
| Kim, HB | 1 |
| Kozakewich, HP | 1 |
| Marcus, KJ | 1 |
| Shamberger, RC | 1 |
| Weldon, CB | 1 |
| Kim, YD | 1 |
| Kim, KJ | 1 |
| Lee, YH | 1 |
| Janeway, KA | 1 |
| Grier, HE | 2 |
| Sarhan, OM | 1 |
| El-Baz, M | 1 |
| Sarhan, MM | 1 |
| Ghali, AM | 1 |
| Ghoneim, MA | 1 |
| Scholz, M | 1 |
| Engert, A | 1 |
| Franklin, J | 1 |
| Josting, A | 1 |
| Diehl, V | 1 |
| Hasenclever, D | 1 |
| Loeffler, M | 1 |
| Blot, E | 1 |
| Decaudin, D | 1 |
| Veyradier, A | 1 |
| Bardier, A | 1 |
| Zagame, OL | 1 |
| Pouillart, P | 1 |
| Kawakami, K | 1 |
| Watanabe, Y | 1 |
| Kadowaki, S | 1 |
| Christodoulou, J | 1 |
| Schoch, C | 1 |
| Schnittger, S | 1 |
| Haferlach, T | 1 |
| Krasin, MJ | 1 |
| Rodriguez-Galindo, C | 1 |
| Billups, CA | 1 |
| Davidoff, AM | 1 |
| Neel, MD | 1 |
| Merchant, TE | 1 |
| Kun, LE | 1 |
| Berrak, SG | 1 |
| Pearson, M | 1 |
| Berberoğlu, S | 1 |
| Ilhan, IE | 1 |
| Jaffe, N | 1 |
| Wierecky, J | 1 |
| Kollmannsberger, C | 1 |
| Boehlke, I | 1 |
| Kuczyk, M | 1 |
| Schleicher, J | 1 |
| Schleucher, N | 1 |
| Metzner, B | 1 |
| Kanz, L | 2 |
| Hartmann, JT | 1 |
| Bokemeyer, C | 1 |
| La, TH | 1 |
| Meyers, PA | 3 |
| Wexler, LH | 1 |
| Alektiar, KM | 1 |
| Healey, JH | 1 |
| Laquaglia, MP | 1 |
| Boland, PJ | 1 |
| Wolden, SL | 1 |
| Takizawa, A | 1 |
| Miura, T | 1 |
| Fujinami, K | 1 |
| Osada, Y | 1 |
| Tanaka, M | 2 |
| Maruta, I | 1 |
| Antoneli, CB | 1 |
| Ribeiro, Kde C | 1 |
| Sakamoto, LH | 1 |
| Chojniak, MM | 1 |
| Novaes, PE | 1 |
| Arias, VE | 1 |
| Ruiz Tovar, J | 1 |
| Reguero Callejas, ME | 1 |
| Arano Bermejo, JI | 1 |
| Capote Armas, LF | 1 |
| González-Palacios Martínez, F | 1 |
| Cabañas Navarro, L | 1 |
| Bedano, PM | 1 |
| Bonnin, J | 1 |
| Einhorn, LH | 1 |
| Bhatia, S | 1 |
| Krailo, MD | 1 |
| Chen, Z | 1 |
| Burden, L | 1 |
| Askin, FB | 1 |
| Dickman, PS | 1 |
| Link, MP | 1 |
| Perlman, EJ | 1 |
| Rausen, AR | 1 |
| Robison, LL | 1 |
| Vietti, TJ | 1 |
| Miser, JS | 1 |
| Venkitaraman, R | 1 |
| Affolter, A | 1 |
| Ahmed, M | 1 |
| Thomas, V | 1 |
| Pritchard-Jones, K | 1 |
| Sharma, AK | 1 |
| Marais, R | 1 |
| Nutting, CM | 1 |
| Carpentier, AF | 1 |
| Chantelard, JV | 1 |
| Henin, D | 1 |
| Poisson, M | 1 |
| Hattori, M | 1 |
| Yamazaki, Y | 1 |
| Nakahara, Y | 1 |
| Tsushita, K | 1 |
| Utumi, M | 1 |
| Rialland, X | 1 |
| Pein, F | 1 |
| Saint-Andre, JP | 1 |
| Flamant, F | 1 |
| Bergeron, C | 1 |
| Le Moine, P | 1 |
| Le Prise-Fleury, E | 1 |
| Jouan, H | 1 |
| Tass, P | 1 |
| Darcel, F | 1 |
| Chatel, M | 1 |
| Edan, C | 1 |
| Patte, C | 1 |
| Faivre, J | 1 |
| Soslow, RA | 1 |
| Davis, RE | 1 |
| Warnke, RA | 1 |
| Cleary, ML | 1 |
| Kamel, OW | 1 |
| Malhaire, JP | 1 |
| Labat, JP | 1 |
| Simon, H | 1 |
| Le Maux, H | 1 |
| Spindler, P | 1 |
| Lucas, B | 1 |
| Lamezec, B | 1 |
| Cefalo, G | 1 |
| Tesoro-Tess, JD | 1 |
| Gianni, MC | 1 |
| Fossati-Bellani, F | 1 |
| Lombardi, F | 1 |
| Massimino, M | 1 |
| Enblad, G | 1 |
| Hagberg, H | 1 |
| Gustavsson, A | 1 |
| Glimelius, B | 1 |
| Kushner, BH | 1 |
| Heller, G | 1 |
| Cheung, NK | 1 |
| Wollner, N | 1 |
| Kramer, K | 1 |
| Bajorin, D | 1 |
| Polyak, T | 1 |
| Dunst, J | 2 |
| Ahrens, S | 2 |
| Paulussen, M | 2 |
| Rübe, C | 1 |
| Winkelmann, W | 1 |
| Zoubek, A | 3 |
| Harms, D | 2 |
| Jürgens, H | 2 |
| Orlandi, E | 1 |
| Lazzarino, M | 1 |
| Bernasconi, P | 1 |
| Astori, C | 1 |
| Bernasconi, C | 1 |
| Fetscher, S | 1 |
| Brugger, W | 1 |
| Engelhardt, R | 1 |
| Hasse, J | 1 |
| Frommhold, H | 1 |
| Lange, W | 1 |
| Mertelsmann, R | 1 |
| Schneider, DT | 1 |
| Hilgenfeld, E | 1 |
| Schwabe, D | 1 |
| Behnisch, W | 1 |
| Wessalowski, R | 1 |
| Göbel, U | 2 |
| Bacci, G | 1 |
| Ferrari, S | 1 |
| Bertoni, F | 1 |
| Ruggieri, P | 1 |
| Picci, P | 1 |
| Longhi, A | 1 |
| Casadei, R | 1 |
| Fabbri, N | 1 |
| Forni, C | 1 |
| Versari, M | 1 |
| Campanacci, M | 1 |
| Loehrer, PJ | 1 |
| Wick, MR | 1 |
| Lovett, BD | 1 |
| Lo Nigro, L | 1 |
| Rappaport, EF | 1 |
| Blair, IA | 1 |
| Osheroff, N | 1 |
| Zheng, N | 1 |
| Megonigal, MD | 1 |
| Williams, WR | 1 |
| Nowell, PC | 1 |
| Felix, CA | 1 |
| De Giorgi, U | 1 |
| Rosti, G | 1 |
| Papiani, G | 1 |
| Marangolo, M | 1 |
| Lehnert, M | 1 |
| Taeger, D | 1 |
| Hense, HW | 1 |
| Wagner, A | 1 |
| Reiter, A | 1 |
| Henze, G | 1 |
| Niemeyer, C | 1 |
| Kremens, B | 1 |
| Fölsch, UR | 1 |
| Aulitzky, WE | 1 |
| Voûte, PA | 1 |
| Postovsky, S | 1 |
| Beck, D | 1 |
| Ben-Izhak, O | 1 |
| Arush, MW | 1 |
| Arai, N | 1 |
| Annoh, S | 1 |
| Kaneko, H | 1 |
| Umeda, M | 1 |
| Tsukahara, T | 1 |
| Shirai, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tiss[NCT00643565] | Phase 2 | 154 participants (Actual) | Interventional | 2008-07-29 | Completed | ||
| A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005][NCT00379457] | Phase 3 | 600 participants (Anticipated) | Interventional | 2006-06-30 | Recruiting | ||
| Pegylated-liposome Doxorubicin Combined With Ifosfamide As First-line Treatment for Patients With Advanced or Metastatic Soft Tissue Sarcoma[NCT03268772] | Phase 2 | 40 participants (Actual) | Interventional | 2015-04-01 | Active, not recruiting | ||
| A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors[NCT00923351] | Phase 1/Phase 2 | 44 participants (Actual) | Interventional | 2007-06-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. AUCss is expressed in milligrams times days per milliliter (mg*day/mL). (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase
| Intervention | mg*day/mL (Mean) |
|---|---|
| Bevacizumab + Chemotherapy | 1010 |
CL is a quantitative measure of the rate at which a drug substance is removed from the body. CL is expressed in milliliters per day (mL/day). (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)
| Intervention | mL/day (Mean) |
|---|---|
| Bevacizumab + Chemotherapy | 167 |
Duration of Response was defined as time between first objective response and the occurrence of an EFS event (described in Outcome Measure 1). Objective response was defined in Outcome Measure 3. Median duration of response was estimated using Kaplan-Meier estimates and 95% CI for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years
| Intervention | months (Median) |
|---|---|
| Chemotherapy | NA |
| Bevacizumab + Chemotherapy | 17.48 |
EFS was defined as the time between randomization and occurrence of EFS event. EFS events are described in Outcome Measure 1. Median EFS was estimated using Kaplan-Meier estimates and 95% confidence intervals (CI) for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)
| Intervention | months (Median) |
|---|---|
| Chemotherapy | 14.85 |
| Bevacizumab + Chemotherapy | 20.63 |
Half-life is the time measured for the plasma concentration to decrease by one half. (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)
| Intervention | days (Mean) |
|---|---|
| Bevacizumab + Chemotherapy | 20.8 |
Overall survival was defined as the time between randomization and death due to any cause. Participants without an event were censored at the last time they were known to be alive. Median overall survival was estimated using Kaplan-Meier estimates and 95% CI for median was computed using the method of Brookmeyer and Crowley. (NCT00643565)
Timeframe: Screening up to approximately 10.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)
| Intervention | months (Median) |
|---|---|
| Chemotherapy | 24.02 |
| Bevacizumab + Chemotherapy | 32.79 |
(NCT00643565)
Timeframe: Screening up to approximately 10.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years.
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy | 50 |
| Bevacizumab + Chemotherapy | 51.4 |
EFS events was described in Outcome Measure 1 and Outcome Measure 3. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy | 40.7 |
| Bevacizumab + Chemotherapy | 76.5 |
EFS events included tumor progression (IRC assessed), no evidence of response after 3 cycles of induction (derived from IRC assessment), second primary cancer, or death due to any cause. Data for participants who had not experienced an event by the time of clinical cut-off were censored at the date of the last disease assessment prior to the clinical cut-off date. Data for participants who did not have any post-baseline disease assessments were censored at the time of randomization. Tumor progression was defined using Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0) as at least a 20% increase in the disease measurement, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions, or evidence of clinical progression and unequivocal progression of existing non-target lesions. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years (assessed at screening, Cycles 4, 7 of induction phase, Cycles 1, 4, 7, 10 of maintenance, then every 3 months for 1.5 years and thereafter every 6 months for 2.5 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy | 52.5 |
| Bevacizumab + Chemotherapy | 68.9 |
Objective response prior to first local therapy (surgery and/or radiotherapy) was defined as complete response (CR) or partial response (PR) determined on two consecutive occasions >/=4 weeks apart. Tumor response was assessed as per IRC using RECIST v1.0. CR was defined as disappearance of all target and non-target lesions. If immunocytology was available, no disease was to be detected by that methodology. PR was defined as at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study entry. (NCT00643565)
Timeframe: Screening up to approximately 6.75 years
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy | 36.0 |
| Bevacizumab + Chemotherapy | 54.0 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state. (NCT00643565)
Timeframe: Pre- and within 3 hours post-dose on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycle 2-4 of induction phase (1 cycle = 3 weeks)
| Intervention | mL (Mean) |
|---|---|
| Bevacizumab + Chemotherapy | 2070 |
"A positive response to the tumor vaccine requires a positive reaction in at least one of the two assays below (immune responses to tumor lysates using ex vivo and delayed type of hypersensitivity (DTH).~The presence of a positive delayed type of hypersensitivity (DTH) reaction to the tumor lysate in a patient who did not show a positive DTH reaction prior to immunotherapy. A positive reaction is induration of at least 0.5 cm.~Immunotherapy administered to patients with recurrent or metastatic pediatric solid tumors such as Ewing's sarcoma, rhabdomyosarcoma, or neuroblastoma. Each vaccine is given as 6 separate injections. Three intradermal on one arm or leg and three subcutaneous on the other arm or leg." (NCT00923351)
Timeframe: Week 8, 14, 20 (Arm A) and on Days 42, 84 and 126 (± 7 days) (Arm B)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Participants Who Did Not Receive rhIL-7 | 0 |
| Arm B - Participants Who Received rhIL-7 | 15 |
Overall survival is defined as the time between the first day of treatment to the day of death. (NCT00923351)
Timeframe: Time between the first day of treatment to the day of death or at the conclusion of 5 years of follow-up, whichever comes first, assessed up to approximately 11 years.
| Intervention | years (Median) |
|---|---|
| Arm A - Participants Who Did Not Receive rhIL-7 | 2.4 |
| Arm B - Participants Who Received rhIL-7 | 4.3 |
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00923351)
Timeframe: Date treatment consent signed to date off study, approximately 49.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Participants Who Did Not Receive rhIL-7 | 6 |
| Arm B - Participants Who Received rhIL-7 | 24 |
10 reviews available for ifosfamide and Cancer, Second Primary
| Article | Year |
|---|---|
Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature.
Topics: Bone Neoplasms; Cisplatin; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Second Primary; Osteosa | 2022 |
Paraspinal synovial sarcoma as an unusual postradiation complication in pediatric abdominal neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 18; Chromosomes, Human, X; | 2008 |
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; H | 2010 |
Bilateral Wilms' tumors: single-center experience with 22 cases and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Child, Preschool; Com | 2010 |
Trilateral retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Combined Modality Thera | 2007 |
Translocation t(11;19) (q23;p13) in a child with myelomonocytic leukemia following 2 years after chemotherapy for pneumoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Chromosomes, Human, Pair 11; Chrom | 1993 |
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc | 1993 |
Thymic malignancies.
Topics: Adrenal Cortex Hormones; Agammaglobulinemia; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2001 |
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical T | 2002 |
Secondary thyroid carcinoma after treatment for clear cell carcinoma of the uterus: case report and review of the literature.
Topics: Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2001 |
7 trials available for ifosfamide and Cancer, Second Primary
| Article | Year |
|---|---|
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
Metastatic Rhabdomyosarcoma: Results of the European
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Disease-Free | 2022 |
Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Neoplasms, Second P | 2022 |
Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Ch | 2007 |
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Res | 1998 |
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cis | 1999 |
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2000 |
Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2001 |
31 other studies available for ifosfamide and Cancer, Second Primary
| Article | Year |
|---|---|
Outcomes of Pediatric Patients With Metastatic Ewing Sarcoma Treated With Interval Compression.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2023 |
A report on second neo-plasms in seven children with solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisp | 2022 |
Double recurrence of double cancers: Rhabdomyosarcoma and secondary AML.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Fatal Outco | 2020 |
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla | 2017 |
Secondary malignant neoplasms after osteosarcoma: early onset and cumulative alkylating agent dose dependency.
Topics: Adolescent; Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 2015 |
Ewing Sarcoma of the Bone With EWS/FLI1 Translocation After Successful Treatment of Primary Osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Cisplatin; Combined Modality The | 2017 |
Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Secondary leukemia in a child conceived using in vitro fertilization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Child, | 2008 |
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine | 2011 |
Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.
Topics: ADAM Proteins; ADAMTS13 Protein; Adenocarcinoma; Anemia, Hemolytic; Antineoplastic Combined Chemothe | 2002 |
[Therapy-related acute myelogenous leukemia (AML-M6) with add(11) (q23) and del(20) (q11.2) developing via myelodysplastic syndrome after chemotherapy for malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; | 2003 |
Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Cisplatin; Etopo | 2004 |
Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil | 2004 |
High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Female; Hu | 2005 |
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Etopo | 2005 |
Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2006 |
[A case of therapy-related leukemia/myelodysplastic syndrome following treatment of refractory testicular germ cell tumor].
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Ci | 2005 |
Malignant mixed Mullerian tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemo | 2006 |
Metachronous intracranial germinoma in a patient with a previous primary mediastinal seminoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Cisplatin; Combin | 2006 |
Childhood papillary thyroid cancer as second malignancy after successful treatment of rhabdomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Combined Modality | 2008 |
Osteosarcoma following radiation treatment for meningioma: report of a case and effective treatment with chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cisplatin; Dacti | 1994 |
Detection of major and minor bcr/abl fusion gene transcripts in a patient with acute undifferentiated leukemia secondary to treatment with an alkylating agent.
Topics: Acute Disease; Alkylating Agents; Anemia, Sideroblastic; Base Sequence; Cell Transformation, Neoplas | 1995 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplati | 1996 |
One case of Stewart-Treves syndrome successfully treated at two years by chemotherapy and radiation therapy in a 73-year-old woman.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic | 1997 |
Treatment of childhood post-irradiation sarcoma of bone in cancer survivors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1997 |
Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Fem | 1998 |
Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 1998 |
Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1998 |
Acute myelogenous leukemia after treatment for malignant germ cell tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Cisp | 1999 |
Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Catechols; Child; Chromosome Bre | 2001 |
[Elderly non-Hodgkin's lymphoma presenting with pulmonary squamous cell carcinoma as a complication of chemotherapy for malignant lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophosphamide; Hu | 1992 |